178 related articles for article (PubMed ID: 14693524)
1. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Adamis T; Laoutaris G; Sabracos L; Koussoulas V; Mouktaroudi M; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Jan; 48(1):93-9. PubMed ID: 14693524
[TBL] [Abstract][Full Text] [Related]
2. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Antonopoulou A; Raftogiannis M; Koutoukas P; Tsaganos T; Tziortzioti V; Panagou C; Adamis T; Giamarellou H
BMC Infect Dis; 2006 Feb; 6():31. PubMed ID: 16504031
[TBL] [Abstract][Full Text] [Related]
3. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
Giamarellos-Bourboulis EJ; Tziortzioti V; Koutoukas P; Baziaka F; Raftogiannis M; Antonopoulou A; Adamis T; Sabracos L; Giamarellou H
J Antimicrob Chemother; 2006 May; 57(5):937-44. PubMed ID: 16549515
[TBL] [Abstract][Full Text] [Related]
4. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
Giamarellos-Bourboulis EJ; Baziaka F; Antonopoulou A; Koutoukas P; Kousoulas V; Sabracos L; Panagou C; Perrea D; Giamarellou H
Int J Antimicrob Agents; 2005 Feb; 25(2):168-72. PubMed ID: 15664488
[TBL] [Abstract][Full Text] [Related]
5. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
Giamarellos-Bourboulis E; Adamis T; Sabracos L; Raftogiannis M; Baziaka F; Tsaganos T; Koutoukas P; Plachouras D; Karayannacos P; Giamarellou H
Scand J Infect Dis; 2005; 37(1):48-54. PubMed ID: 15764190
[TBL] [Abstract][Full Text] [Related]
6. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
Baziaka F; Giamarellos-Bourboulis EJ; Raftogiannis M; Adamis T; Tziortzioti V; Sabracos L; Chrisofos M; Koutoukas P; Giamarellou H; Douzinas EE
J Chemother; 2008 Feb; 20(1):63-8. PubMed ID: 18343746
[TBL] [Abstract][Full Text] [Related]
8. The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa.
Koussoulas V; Giamarellos-Bourboulis EJ; Adamis T; Mouktaroudi M; Sabracos L; Perrea D; Giamarellou H; Dionyssiou-Asteriou A
Prostaglandins Leukot Essent Fatty Acids; 2005 Jan; 72(1):41-7. PubMed ID: 15589398
[TBL] [Abstract][Full Text] [Related]
9. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Geladopoulos T; Chrisofos M; Koutoukas P; Vassiliadis J; Alexandrou I; Tsaganos T; Sabracos L; Karagianni V; Pelekanou E; Tzepi I; Kranidioti H; Koussoulas V; Giamarellou H
Shock; 2006 Oct; 26(4):410-6. PubMed ID: 16980890
[TBL] [Abstract][Full Text] [Related]
10. Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa.
Dimopoulos G; Theodorakopoulou M; Armaganidis A; Tzepi IM; Lignos M; Giamarellos-Bourboulis EJ; Tsaganos T
J Surg Res; 2015 Sep; 198(1):175-84. PubMed ID: 26073350
[TBL] [Abstract][Full Text] [Related]
11. Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.
Tsovolou EC; Tzepi IM; Spyridaki A; Tsaganos T; Karagianni V; Menenakos E; Liakou P; Sabracos L; Zografos G; Giamarellos-Bourboulis EJ
APMIS; 2014 Jan; 122(1):68-75. PubMed ID: 23656439
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
Giamarellos-Bourboulis EJ; Bolanos N; Laoutaris G; Papadakis V; Koussoulas V; Perrea D; Karayannacos PE; Giamarellou H
BMC Infect Dis; 2005 Jun; 5():51. PubMed ID: 15978135
[TBL] [Abstract][Full Text] [Related]
13. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.
Giamarellos-Bourboulis EJ; Koussoulas V; Panagou C; Adamis T; Baziaka F; Skiadas I; Perrea D; Dionyssiou-Asteriou A; Giamarellou H
Int J Antimicrob Agents; 2004 Oct; 24(4):357-61. PubMed ID: 15380261
[TBL] [Abstract][Full Text] [Related]
14. Early apoptosis of blood monocytes is a determinant of survival in experimental sepsis by multi-drug-resistant Pseudomonas aeruginosa.
Antonopoulou A; Raftogiannis M; Giamarellos-Bourboulis EJ; Koutoukas P; Sabracos L; Mouktaroudi M; Adamis T; Tzepi I; Giamarellou H; Douzinas EE
Clin Exp Immunol; 2007 Jul; 149(1):103-8. PubMed ID: 17488299
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant Pseudomonas aeruginosa.
Tzepi IM; Giamarellos-Bourboulis EJ; Carrer DP; Tsaganos T; Claus RA; Vaki I; Pelekanou A; Kotsaki A; Tziortzioti V; Topouzis S; Bauer M; Papapetropoulos A
J Pharmacol Exp Ther; 2012 Nov; 343(2):278-87. PubMed ID: 22859861
[TBL] [Abstract][Full Text] [Related]
16. Reverse kinetics of angiopoietin-2 and endotoxins in acute pyelonephritis: Implications for anti-inflammatory treatment?
Safioleas K; Giamarellos-Bourboulis EJ; Carrer DP; Pistiki A; Sabracos L; Deliveliotis C; Chrisofos M
Cytokine; 2016 May; 81():28-34. PubMed ID: 26844659
[TBL] [Abstract][Full Text] [Related]
17. Early cutaneous alterations in experimental sepsis by Pseudomonas aeruginosa.
Petropoulou H; Giamarellos-Bourboulis EJ; Kavatzas N; Stratigos A; Mouktaroudi M; Adamis T; Baziaka F; Katsambas AD; Stavrianeas NG
Dermatology; 2004; 209(2):111-6. PubMed ID: 15316164
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study.
Giamarellos-Bourboulis EJ; Plachouras D; Tzivra A; Kousoulas V; Bolanos N; Raftogiannis M; Galani I; Dontas I; Dionyssiou-Asteriou A; Giamarellou H
Clin Exp Immunol; 2004 Feb; 135(2):240-6. PubMed ID: 14738451
[TBL] [Abstract][Full Text] [Related]
19. Multidrug-resistant Pseudomonas aeruginosa: a case of pyelonephritis and herbal therapy.
Tong Y; Sun M; Wang C
J Altern Complement Med; 2014 Feb; 20(2):142-4. PubMed ID: 23869971
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Plachouras D; Skiathitis S; Raftogiannis M; Dionyssiou-Asteriou A; Dontas I; Karayannacos PE; Giamarellou H
J Antimicrob Chemother; 2003 Feb; 51(2):423-6. PubMed ID: 12562715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
